Poster preview
ePoster
MITOCHONDRIAL METABOLISM INHIBITION AS A NEW THERAPEUTIC STRATEGY AGAINST MEDULLOBLASTOMA
Irene Chavarría Cubeland 4 co-authors
Traslational Research Unit, Hospital Universitario Miguel Servet, IIS Aragón
FENS Forum 2026 (2026)
Barcelona, Spain
Board PS06-09PM-019
Presentation
Date TBA
Board: PS06-09PM-019
Event Information
Poster Board
PS06-09PM-019
Poster
View posterAbstract
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Although prognosis has significantly improved, 25–30% of patients still die from the disease. Our work focuses on Group 3 (G3) and Group 4 (G4), the subtypes with the poorest prognosis and highest metastatic rates. Our initial studies suggested that Medulloblastoma Cancer Stem Cells (MB-CSCs), a chemoresistant subpopulation implicated in metastasis and recurrence, rely on mitochondrial metabolism for proliferation and survival. Thus, we hypothesized that mitochondrial inhibition would improve treatment efficacy in G3 (D425, MB002) and G4 (CHLA‑01‑Med) cellular models. First, we screened different metabolic inhibitors and found that the respiratory complex I inhibitor metformin selectively induced cell death in MB-CSC enrichment models and reduced self‑renewal in vitro, although it did not consistently improve survival in vivo. Next, we evaluated triptolide, which significantly decreased stem cell frequency, improved overall survival in vivo, and showed synergistic activity with chemotherapy. In parallel, and considering the inconsistency between in vitro and in vivo results, we are developing a novel MB‑on‑chip platform that better recapitulates the tumor microenvironment and provides a more predictive system for assessing therapeutic responses. Our results support mitochondrial inhibition, using the compound triptolide, as a promising strategy to target MB‑CSCs, improving MB treatment. Our study represents a proof-of-concept for the value of medulloblastoma‑on‑chip model as a novel technological approach that may enhance the translational relevance of in vitro assays and ultimately serve as a platform for more reliable drug screening in MB.
Recommended posters
IDENTIFICATION OF NOVEL COMBINATORIAL TREATMENTS TO DRIVE GLIOBLASTOMA STEM CELLS OUT OF STEMNESS IN 2D AND 3D ORGANOID MODELS
Anne Lorenz, Megan Maloney, Chenyun Cao, Laura Morcom, Yuxin Lan, Fajar Msood, David Rowitch, Anna Philpott, Michele Mishto, Roberta Azzarelli
SYNERGY OF CONCURRENT PI3K-MAPK INHIBITION IN GLIOBLASTOMA STEM CELLS: VIABILITY, MORPHOLOGICAL CHANGES AND IN VIVO HISTOPATHOLOGY
Elisa Arias Romero, Enrique Jiménez-Madrona, María Martínez-Fernández, Arantxa Tabernero, Maruan Hijazi
THE EFFECT OF STABILIZING OR INHIBITING HYPOXIA-INDUCIBLE FACTORS ON THE TREATMENT OF GLIOBLASTOMA CELLS WITH METFORMIN
Moritz Langer, Martin Hadamitzky, Joachim Fandrey, Tristan Leu
ADDRESSING MITOCHONDRIAL DYNAMICS IN INTERCELLULAR TRANSFER TO GLIOBLASTOMA
Andrea Valiño Torres, Álvaro Morcuende Campos, Rubén Quintana Cabrera
TISSUE STIFFNESS AS A KEY REGULATOR OF BRAIN TUMOR-INITIATING CELLS
Julia Carrillo García, Ali Momin, Qi Yang, Eric Sass, Hyun-Kee Min, Guanqiao Shan, Zheyuan Gong, Li Ruicheng, Min Zhu, Zhengchao Dou, Elliot Ying, Yi Xiong, Xin Chen, Chi-Chung Hui, Sevan Hopyan, Siyi Wanggou, Xian Wang, Yu Sun, Xi Huang
SYNERGISTIC CO-TARGETING OF DNA GLYCOSYLASE NEIL1 AND G-QUADRUPLEX STRUCTURES UNCOVERS NOVEL THERAPEUTIC OPPORTUNITIES IN GLIOBLASTOMA
Miroslava Kissova, Aleksandr Ianevski, Maria Camara-Quilez, Erlend Ravlo, Marthe V Vestvik, Hannah Lovise Bjørkavoll Lervåg, Marte Andresen Skjelle, Anna Høyem Lademo, Natalia Kostilek, Wei Wang, Vidar Langseth Saasen, Alessandro Brambilla, Karin Garten, Per Arne Aas, Nina-Beate Liabakk, Xiaolin Lin, Nathalie Jurisch-Yaksi, Øyvind Jacobsen, Tora Skeidsvoll Solheim, Anne Jarstein Skjulsvik, Ole Skeidsvoll Solheim, Bjørn Dalhus, Jing Ye, Magnar Bjørås